The Readout Loud
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Mar 27, 2025
Felix Baldov-Lenschen, CEO of Altus Labs, shares insights on his company's innovative AI tool for cancer drug development, called IPRO, which excels in predicting patient survival. The discussion touches on the recent turmoil in health agencies, with job cuts and a significant drug approval for a rare disease. Felix reveals how AI is reshaping oncology, enhancing treatment assessments, and improving clinical trial efficiency. The bankruptcy of 23andMe also emerges as a cautionary tale for biotech, highlighting challenges in the industry.
31:25
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The Trump administration's job cuts in health agencies could severely disrupt FDA operations and future regulatory interactions for biotech firms.
- 23andMe's bankruptcy and CEO resignation reflect struggles in the genetic testing industry, raising concerns about the future of its extensive health data.
Deep dives
AI's Edge in Cancer Detection
An AI-based tool has demonstrated the potential to more accurately detect tumor shrinkage and predict patient survival in cancer clinical trials compared to traditional human assessments. The technology, developed by an AI startup, utilizes extensive imaging data to analyze not just tumor size, but the entire disease burden present in patients. This innovative approach allows for a more nuanced understanding of factors influencing survival, including various patient characteristics that human radiologists may overlook. The promising results suggest a shift in how future clinical trials may be designed and analyzed.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
